Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Medication Guide

Phenylpropanolamine

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Scored Chewable Tablets Multiple FDA sponsors Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Phenylpropanolamine

Phenylpropanolamine

Drug type: Generic ingredient • Generic profile No FDA branded products linked

Both Scored Chewable Tablets Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Phenylpropanolamine

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs. Species commonly shown: Both, Dog.

Generic name
Phenylpropanolamine
Brand names
PROIN® Chewable Tablets, PROIN ER™, Phenylpropanolamine Hydrochloride
Manufacturer
Multiple FDA sponsors
Species
Both, Dog
Dosage forms
Scored Chewable Tablets, Tablet, Chewable Tablets
Prescription
Prescription required
Completeness
100%
Validation
Needs review
Brand names
PROIN® Chewable Tablets PROIN ER™ Phenylpropanolamine Hydrochloride
Dosage forms
Scored Chewable Tablets Tablet Chewable Tablets

Indications / Uses

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Death by euthanasia, Elevated alanine aminotransferase (ALT), Urinary incontinence.

FAQ

Both, Dog

Yes. Roxee shows this as prescription-only.

Scored Chewable Tablets, Tablet, Chewable Tablets

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • Falling (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Phenylpropanolamine; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-054385
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 30 serious reports; 1 species group. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-054385
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-054385
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Falling (1 reports), Enlarged liver (1 reports), Elevated symmetrical dimethylarginine (1 reports)

Body systems represented Signal grouping

Digestive (3), Neurologic (2), Behavior (3), Other (24)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (32 reports)

Breed metadata in reports Metadata only

Shepherd Dog - German (2), Retriever - Labrador (1), ['Terrier - Bull - American Pit', 'Dog (unknown)'] (1), Collie - Smooth-haired (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Phenylpropanolamine fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Vomiting, wobbly/unsteady walking, Falling

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Phenylpropanolamine brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-054385 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Vomiting
  • wobbly/unsteady walking
  • Falling

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Falling (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Dog
Indication / use
For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.
Form / route / dose
Form: Chewable Tablets, Scored Chewable Tablets, Tablet
Route: Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Chewable Tablets, Scored Chewable Tablets, Tablet
Identifiers:
ANADA: 200787 NADA: 141324 NADA: 141517 NDC Package: 49427-141-48 NDC Package: 49427-141-50 NDC Package: 49427-315-48 NDC Package: 49427-315-50 NDC Package: 49427-316-48 NDC Package: 49427-316-50 NDC Package: 49427-344-44 NDC Package: 49427-344-57 NDC Package: 49427-345-44 NDC Package: 49427-345-57 NDC Package: 49427-346-44 NDC Package: 49427-346-57 NDC Package: 49427-347-44 NDC Package: 49427-347-57 NDC Package: 86117-042-05 NDC Package: 86117-042-09 NDC Package: 86117-043-05
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
13
Matching reports
4
Active filters
1
Selected filters
Reaction: Urinary incontinence Clear
Reset
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-013509

Received 2026-03-23 · MSK · MSK

Serious
Species
Dog
Breed
['Terrier - Bull - American Pit', 'Dog (unknown)']
Size / weight
25-49 lb (21.863 Kilogram)
Age
8+ years (13 Year)
Sex
Female Unknown
Region
USA
Reactions
Elevated creatinineInappropriate urinationPolyuriaInappropriate defecationUrinary incontinenceTail paralysisStranguriaArthritisSpondylosis
Body systems
Other
Outcomes
Ongoing

USA-USFDACVM-2025-US-075305

Received 2025-12-22 · MSK · MSK

Non-serious
Species
Dog
Breed
Bulldog - English
Size / weight
50-99 lb (29.94 Kilogram)
Age
8+ years (11.2 Year)
Sex
Female Unknown
Region
USA
Reactions
Urinary incontinence
Body systems
Other
Outcomes
Ongoing

USA-USFDACVM-2025-US-072884

Received 2025-12-10 · MSK · MSK

Serious
Species
Dog
Breed
['Pointer (unspecified)', 'Collie - Border']
Size / weight
50-99 lb (22.68 Kilogram)
Age
8+ years (15 Year)
Sex
Female Unknown
Region
USA
Reactions
AnxietyVocalisationBehavioural disorder NOSDiarrhoeaBiting -aggression (see also Skin and appendages disorders)PacingFrequent urinationInappropriate defecationInappropriate urinationCognitive disorder NOSSeizure NOSVocalizing while sleepingUnconsciousNystagmusDifficulty standingUnable to walkVestibular disorder NOSLimb non-weight bearingFallingUrinary incontinenceMedication error NOSPantingAbnormal posture NOS
Body systems
BehaviorOtherDigestiveNeurologic
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-070900

Received 2025-12-01 · MSK · MSK

Non-serious
Species
Dog
Breed
['Retriever (unspecified)', 'Dog (unknown)']
Size / weight
50-99 lb (38.555 Kilogram)
Age
8+ years (13 Year)
Sex
Female Neutered
Region
USA
Reactions
Urinary incontinence
Body systems
Other
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
30
Species represented
1
Grouped by Body System
Digestive (3) · Vomiting, Diarrhea, Bloody diarrhoea Neurologic (2) · Unsteady walking (ataxia), Depression Behavior (3) · Biting -aggression, Behavioral disorder (unspecified), Anxiety Other (24) · Falling, Enlarged liver, Elevated symmetrical dimethylarginine
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (32)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Behavior Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

3

FOI

3

Phenylpropanolamine Hydrochloride

SPL · SPL

FDA Structured Product Label

Phenylpropanolamine Hydrochloride

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
ZyVet Animal Health, Inc.
ANADA
200-787
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
25, 50, or 75 mg phenylpropanolamine hydrochloride per tablet

Dogs

Indication

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Dosage

The total recommended dosage for oral administration is 2 mg/kg (0.91 mg/lb) of body weight twice daily. Phenylpropanolamine Hydrochloride is scored and dosage should be calculated in half-tablet increments.

PROIN ER™

SPL · SPL

FDA Structured Product Label

PROIN ER™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
NADA
141-517
Status
RX
Form
Tablet
Route
Oral
Species
Dog
Composition / specifications
18, 38, 74, or 145 mg of phenylpropanolamine hydrochloride per tablet

Dogs

Indication

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Dosage

The recommended dosage is 2 to 4 mg/kg (0.9 to 1.8 mg/lb) of body weight once daily. Administer with food. Do not split or crush tablets. Dogs weighing less than 10 pounds cannot be safely dosed because tablet administration would result in a dose over 4 mg/kg.

PROIN® Chewable Tablets

SPL · SPL

FDA Structured Product Label

PROIN® Chewable Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
NADA
141-324
Status
RX
Form
Scored Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
Each chewable tablet contains 25, 50, or 75 milligram (mg) phenylpropanolamine hydrochloride.

Dogs

Indication
For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.
Dosage
The total recommended dosage for oral administration is 2 mg/kg (0.91 mg/lb) of body weight twice daily. The dosage should be calculated in half-tablet increments.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.

FOI Summary oA 200-787 Approved June 11, 2024.pdf

FOI · FOI

FOI Summary oN 141-517 Approved March 29, 2019.pdf

FOI · FOI

UCM296349.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets, Scored Chewable Tablets, Tablet Oral
Applications: ANADA 200-787 • NADA 141-517 • NADA 141-324
Documents: 3 (FOI: 3) • SPL: 3 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 61 Cat 0 View
Case summaries: 13 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only. (Contraindication, High)
Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Falling (1) Enlarged liver (1) Elevated symmetrical dimethylarginine (1) Elevated serum alkaline phosphatase (1) Elevated renal parameters (1) Elevated protein:creatinine ratio (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200787 NADA: 141324 NADA: 141517 NDC Package: 49427-141-48 NDC Package: 49427-141-50 NDC Package: 49427-315-48 NDC Package: 49427-315-50 NDC Package: 49427-316-48 NDC Package: 49427-316-50 NDC Package: 49427-344-44 NDC Package: 49427-344-57 NDC Package: 49427-345-44 NDC Package: 49427-345-57 NDC Package: 49427-346-44 NDC Package: 49427-346-57 NDC Package: 49427-347-44 NDC Package: 49427-347-57 NDC Package: 86117-042-05 NDC Package: 86117-042-09 NDC Package: 86117-043-05 NDC Package: 86117-043-09 NDC Package: 86117-044-05 NDC Package: 86117-044-09 NDC Package: 86136-127-36
Package NDC Product NDC Form / Route Status
49427-141-48 49427 -
49427-141-50 49427 -
49427-315-48 49427 -
49427-315-50 49427 -
49427-316-48 49427 -
49427-316-50 49427 -
49427-344-44 49427 -
49427-344-57 49427 -
49427-345-44 49427 -
49427-345-57 49427 -
49427-346-44 49427 -
49427-346-57 49427 -
49427-347-44 49427 -
49427-347-57 49427 -
86117-042-05 86117 -
86117-042-09 86117 -
86117-043-05 86117 -
86117-043-09 86117 -
86117-044-05 86117 -
86117-044-09 86117 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 115 Clinical 8 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only. (Clinical, 2026-04-16)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only. (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only. (Clinical, 2026-04-11)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Death by euthanasia, Elevated a… (Clinical, 2026-04-11)
  • usage: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs. (Clinical, 2026-04-16)
  • usage: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs. (Clinical, 2026-04-15)
  • usage: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs. (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only. (Official, 2026-04-22)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only. (Official, 2026-02-12)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-08-06)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-08-05)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-08-04)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-08-03)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-08-02)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-08-01)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-07-31)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-07-30)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-07-29)
  • indications: For the control of urinary incontinence due to urethral sphincter hypotonus in dogs For the control of urinary incontinence due to urethral sphincter hypotonus… (Official, 2026-07-28)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-16 13:29 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-16 13:29 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-16 13:29 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-16 13:29 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 13:29 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 13:29 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 13:29 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 13:29 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 13:29 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Phenylpropanolamine Hydrochloride
RX
Phenylpropanolamine hydrochloride
Chewable Tablets Oral
ZyVet Animal Health, Inc. ANADA 200-787 Approved Jul 1, 2024
PROIN ER™
RX
Phenylpropanolamine hydrochloride
Tablet Oral
Pegasus Laboratories, Inc. NADA 141-517 Approved Apr 1, 2019
PROIN® Chewable Tablets
RX
Phenylpropanolamine hydrochloride
Scored Chewable Tablets Oral
Pegasus Laboratories, Inc. NADA 141-324 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
25, 50, or 75 mg phenylpropanolamine hydrochloride per tablet
Dogs
Indication

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Dosage

The total recommended dosage for oral administration is 2 mg/kg (0.91 mg/lb) of body weight twice daily. Phenylpropanolamine Hydrochloride is scored and dosage should be calculated in half-tablet increments.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
18, 38, 74, or 145 mg of phenylpropanolamine hydrochloride per tablet
Dogs
Indication

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Dosage

The recommended dosage is 2 to 4 mg/kg (0.9 to 1.8 mg/lb) of body weight once daily. Administer with food. Do not split or crush tablets. Dogs weighing less than 10 pounds cannot be safely dosed because tablet administration would result in a dose over 4 mg/kg.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
Each chewable tablet contains 25, 50, or 75 milligram (mg) phenylpropanolamine hydrochloride.
Dogs
Indication
For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.
Dosage
The total recommended dosage for oral administration is 2 mg/kg (0.91 mg/lb) of body weight twice daily. The dosage should be calculated in half-tablet increments.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.

FDA page: Open in Animal Drugs @ FDA

Usage

For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.For oral use in dogs only.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Diarrhea (1) • Dog Bloody diarrhoea (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Depression (1) • Dog

Showing top 5 for Neurologic.

Behavior
Biting -aggression (1) • Dog Behavioral disorder (1) • Dog Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Falling (1) • Dog Enlarged liver (1) • Dog Elevated symmetrical dimethylarginine (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated renal parameters (1) • Dog
Show more (19)
Elevated protein:creatinine ratio (1) • Dog Elevated creatinine (1) • Dog Elevated cholesterol (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated amylase (1) • Dog Elevated alanine aminotransferase (1) • Dog Easily startled (1) • Dog Difficulty standing (1) • Dog Difficulty going up/down stairs (1) • Dog Death by euthanasia (1) • Dog Crying (1) • Dog Cough (1) • Dog Cognitive disorder NOS (1) • Dog Bone and joint disorder NOS (1) • Dog Arthritis (1) • Dog Abnormal radiograph finding (1) • Dog Abnormal posture NOS (1) • Dog Abnormal cytology (1) • Dog Abdominal pain (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Retriever - Labrador, Male, 19 month, 32.205 kilogram • Drug: MSK, Oral, Frequency: 1 per day • Reactions: Lack of efficacy (endoparasite) - tapeworm, Unclassifiable adverse event • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-014484
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 19.00 Month
  • Weight: 32.205 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Frequency: 1 per day
Reactions Reported:
Lack of efficacy (endoparasite) - tapeworm Unclassifiable adverse event
Outcomes: Outcome Unknown

Dog, ['Terrier - Bull - American Pit', 'Dog (unknown)'], Female, 13 year, 21.863 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Elevated creatinine, Inappropriate urination, Polyuria, Inappropriate defecation, Urinary incontinence… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013509
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 21.863 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Elevated creatinine Inappropriate urination Polyuria Inappropriate defecation Urinary incontinence Tail paralysis Stranguria Arthritis Spondylosis
Outcomes: Ongoing

Dog, Collie - Smooth-haired, Female, 11 year, 30.9 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Generalised itching, Increased drinking, Polyuria • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-011585
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 30.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Generalised itching Increased drinking Polyuria
Outcomes: Ongoing

Dog, Shepherd Dog - German, Female, 5 year, 38.918 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Swelling NOS, Lameness, Bone and joint disorder NOS, Abnormal radiograph finding • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013136
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 5.00 Year
  • Weight: 38.918 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Swelling NOS Lameness Bone and joint disorder NOS Abnormal radiograph finding
Outcomes: Ongoing

Dog, Doberman Pinscher, Female, 9 year, 27.21 kilogram • Drug: MSK, Unknown • Reactions: Vomiting, UNPALATABLE • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-009736
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 27.210 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Vomiting UNPALATABLE
Outcomes: Recovered/Normal

Dog, Shepherd Dog - German, Female, 11 year, 20.865 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Vomiting, Not eating, Tiredness (lethargy), Reluctant to move, Seizure NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075421
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 20.865 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Vomiting Not eating Tiredness (lethargy) Reluctant to move Seizure NOS
Outcomes: Ongoing

Dog, Bulldog - English, Female, 11.2 year, 29.94 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Urinary incontinence • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075305
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.20 Year
  • Weight: 29.940 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Urinary incontinence
Outcomes: Ongoing

Dog, ['Shepherd Dog - German', 'Siberian Husky'], Female, 9 year, 34.019 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Difficulty going up/down stairs, Lying down, High leg gait • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-074392
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 34.019 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Difficulty going up/down stairs Lying down High leg gait
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.